Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | MM: AMG 701 BiTE

Yu-Tzu Tai • 15 Sep 2019
IMW 2019
Multiple Myeloma Antibodies

Dr. Yu-Tzu Tai, PhD of the Dana-Farber Cancer Institute, Boston, MA, speaks on recent research which indicates the success of AMG 701, a new Bi-specific T-cell engager (BiTE) both in monotherapy and combination therapy when tackling tumor cells directly. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Yu-Tzu Tai

3:28
Using γ-secretase inhibitors to potentiate the efficacy of BCMA-targeted therapy in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
5:22
Novel target antigens to improve the efficacy of immunotherapeutics in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
1:35
Rationale for using immunotherapies in the frontline treatment of multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
3:09
Reducing CAR-T toxicity
Yu-Tzu Tai • 15 Sep 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals